共刺激分子B7H3与B7H4在T淋巴母细胞淋巴瘤/白血病中的表达及临床意义
该研究采用免疫组化检测100例T-LBL/ALL和30例淋巴结反应性增生中B7H3、B7H4蛋白表达,并用实时荧光定量PCR检测50例T-LBL/ALL和30例LH中mRNA表达。结果显示B7H3、B7H4蛋白阳性率分别为23%和54%,B7H3 mRNA在T-LBL/ALL组为LH组的2.5倍,B7H3 mRNA过表达是预后独立危险因素。
要点
- T-LBL/ALL中B7H3蛋白阳性率23%,B7H4蛋白阳性率54%。
- B7H3 mRNA在T-LBL/ALL组相对表达为LH组的2.5倍。
- B7H3 mRNA过表达是T-LBL/ALL预后独立危险因素(P<0.05)。
核心结论
- B7H3、B7H4表达与T-LBL/ALL临床病理参数及预后密切相关,提示二者在疾病发展中起重要作用。
研究设计与样本
- 回顾性检测2001年1月至2017年6月山西省肿瘤医院诊断的100例T-LBL/ALL(实验组)和30例淋巴结反应性增生(LH,对照组)的B7H3、B7H4蛋白表达。
- 用实时荧光定量PCR检测50例T-LBL/ALL和30例LH中B7H3 mRNA与B7H4 mRNA表达。
- 采用单因素分析及多因素Cox回归分析临床病理特征与预后的关系。
主要发现
- 100例T-LBL/ALL中男性79例、女性21例。
- 免疫组化显示B7H3、B7H4蛋白阳性率分别为23%(23/100)与54%(54/100)。
- 实时荧光定量PCR显示T-LBL/ALL组B7H3 mRNA相对表达为LH组的2.5倍,B7H4 mRNA在两组中表达量均极低。
- 单因素分析显示B7H3蛋白表达与B症状、原发淋巴结内相关(P<0.05),B7H4蛋白表达与纵隔增宽、骨髓累犯相关(P<0.05)。
- B7H3蛋白、B7H3 mRNA、B7H4蛋白表达及国际预后指数评分与预后相关(P<0.05),B7H3和B7H4联合表达与预后相关(P<0.05)。
临床怎么用
- 检测T-LBL/ALL中B7H3蛋白及mRNA表达有助于预后风险评估。
- B7H4蛋白表达与纵隔增宽、骨髓累犯相关,可作为临床病理评估参考。
- B7H3与B7H4联合表达状态可用于T-LBL/ALL预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of B7H3 and B7H4 in T lymphoblastic lymphoma/leukemia (T-LBL/ALL) in correlation with clinicopathological parameters and patient prognosis. Methods: Immunohistochemistry (IHC) was used to detect the expression of B7H3 and B7H4 protein in 100 cases of T-LBL/ALL(test group) and 30 cases of lymph node reactive hyperplasia (LH) (control group), diagnosed at Shanxi Cancer Hospital from January 2001 to June 2017. Real-time RT-PCR was used to detect the mRNA expression of B7H3 and B7H4 in 50 cases of T-LBL/ALL and 30 cases of LH (control group). Results: There were 79 males,21 females. Immunohistochemical results showed that the expression rates of B7H3 and B7H4 were 23%(23/100) and 54%(54/100), respectively. By real-time RT-PCR, the relative expression of B7H3 mRNA in the T-LBL/ALL group was 2.5 times of that of the LH group. The expression levels of B7H4 mRNA in T-LBL/ALL group and LH group were extremely low.Single factor analysis showed that B7H3 protein expression in T-LBL/ALL group was associated with B symptoms and primary nodal disease (P<0.05). B7H4 protein expression was associated with mediastinal broadening and bone marrow involvement (P<0.05). B7H3 protein, B7H3 mRNA, B7H4 protein expression and IPI score were associated with prognosis (P<0.05), and the combined expression of B7H3 and B7H4 was associated with T-LBL/ALL prognosis (P<0.05). Multivariate Cox regression analysis showed that overexpression of B7H3 mRNA was an independent risk factor for the prognosis of patients with T-LBL/ALL (P<0.05). Conclusion: Expression of B7H3 and B7H4 is closely corelated with clinicopathological parameters and prognosis of patients with T-LBL/ALL, suggesting that B7H3 and B7H4 expression play an important role in the development of T-LBL/ALL. 目的: 探讨共刺激分子B7H3、B7H4在T淋巴母细胞淋巴瘤/白血病(T-LBL/ALL)中的表达情况,及其与患者临床病理特征及预后的关系。 方法: 应用免疫组织化学法(IHC)检测2001年1月至2017年6月山西省肿瘤医院诊断的100例T-LBL/ALL(实验组)和30例淋巴结反应性增生(LH,对照组)中B7H3与B7H4蛋白表达,应用即时荧光定量聚合酶链反应(real-time RT-PCR)检测50例T-LBL/ALL和30例LH中B7H3 mRNA与B7H4 mRNA的表达。 结果: (1)男性患者79例,女性患者21例。IHC:T-LBL/ALL组中B7H3、B7H4蛋白阳性率分别为23%(23/100)与54%(54/100)。(2)real-time RT-PCR:T-LBL/ALL组中B7H3 mRNA相对表达是LH组的2.5倍。B7H4 mRNA在T-LBL/ALL组与LH组中表达量均极低。(3)单因素分析:T-LBL/ALL组中B7H3蛋白表达与出现B症状、原发淋巴结内均有相关性(P<0.05)。B7H4蛋白表达与纵隔增宽、骨髓累犯相关(P<0.05)。B7H3蛋白、B7H3 mRNA、B7H4蛋白表达和国际预后指数评分与预后相关(P<0.05),且B7H3和B7H4联合表达与T-LBL/ALL预后相关(P<0.05)。(4)多因素Cox回归分析:B7H3 mRNA表达是影响T-LBL/ALL预后的独立危险因素(P<0.05)。 结论: B7H3、B7H4表达与T-LBL/ALL临床病理参数及预后密切相关,提示B7H3、B7H4表达在T-LBL/ALL的发展中起着重要作用。.
引用
- Zhang GZ, Li J, Bai WQ, et al. [Expression of costimulatory molecules B7H3 and B7H4 in T lymphoblastic lymphoma/leukemia and clinical significance]. Zhonghua Bing Li Xue Za Zhi. 2019. PMID: 31104673. doi:10.3760/cma.j.issn.0529-5807.2019.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。